Fatty liver disease

The U.S. Food and Drug Administration (FDA) has approved Rezdiffra (resmetirom) for the treatment of people with noncirrhotic nonalcoholic steatohepatitis (NASH) — a severe type…

Drinking a small amount of alcohol each day did not raise the mortality risk among people in the early stages of steatotic liver disease…

Weekly injections under the skin of the experimental therapy survodutide significantly reduces the severity of metabolic-associated steatohepatitis (MASH), a severe form of fatty…

Most liver transplant centers in the U.S. continue to use stigmatizing language on their websites that could make people with alcohol-associated liver disease (ALD)…

One year of daily resmetirom, Madrigal Pharmaceuticals’ investigational oral therapy, was shown to successfully treat nonalcoholic steatohepatitis (NASH), a severe type of fatty liver…

Weekly injections of tirzepatide, an approved obesity and diabetes treatment, showed promise in people with nonalcoholic steatohepatitis (NASH) — now known as metabolic dysfunction-associated steatohepatitis…

Denifanstat, Sagimet Biosciences’ experimental therapy, outperformed a placebo at resolving nonalcoholic steatohepatitis (NASH) — a severe form of fatty liver disease —…

ProSciento and OWL Metabolomics are partnering to find eligible participants for clinical trials for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Results from a mouse study of nonalcoholic steatohepatitis were promising for Viking Therapeutics' oral therapy VK2809, now also in a Phase 2 trial.

Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis…